Navigation Links
Particles Detected in Vials from Genzyme's Plant Not Expected to Impact Aldurazyme or Naglazyme
Date:11/13/2009

NOVATO, Calif., Nov. 13 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Genzyme notified the company that, in rare circumstances, it has detected foreign particles in some products filled at the Allston Landing facility. To ensure that patients are not exposed to foreign particles during product administration, Genzyme has issued a "Dear Doctor" letter to all physicians treating patients with enzyme replacement products that it markets, including Aldurazyme. The letter states that foreign particles have been found in some vials filled at Genzyme's Allston Landing facility and reminds physicians, as a preventive measure, to use a 0.2-0.22 micron filter during administration.

For Aldurazyme, this is essentially a reminder as the Aldurazyme approved product label has always recommended the use of a 0.22 micron filter when administering the drug. Accordingly, BioMarin does not expect this letter to have any substantial effect on the usage of Aldurazyme, or on the company's financials. Due to a mutual decision by BioMarin and Genzyme, BioMarin has been transitioning Aldurazyme production to other fill finish facilities. The last fill finish of Aldurazyme at Allston Landing was in September 2008.

BioMarin is committed to taking all efforts to maximize patient safety for all of its products. Similar to the Aldurazyme label, the Naglazyme product label also recommends the use of a 0.22 micron filter prior to administering the drug to patients. Additionally, BioMarin utilizes numerous process controls to minimize the presence of particles in its products, including redundant filtration during the manufacture of drug product.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is in Phase 2 clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase 1/2 clinical development for the treatment of MPS IVA. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the manufacture and supply of Aldurazyme and Naglazyme and the safety profile of these products. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: the actual experience in manufacturing these products, future unexpected adverse event reports, , and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2008 Annual Report on Form 10-K. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin®, Naglazyme® and Kuvan® are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.

    Contact:

    Investors:                          Media:
    Eugenia Shen                        Susan Berg
    BioMarin Pharmaceutical Inc.        BioMarin Pharmaceutical Inc.
    (415) 506-6570                      (415) 506-6594

SOURCE BioMarin Pharmaceutical Inc.


'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. UCSB researchers develop drug delivery system using nanoparticles and lasers
2. AlphaRx Presents Positive Preclinical Data on Zysolin(TM) Inhalable Nanoparticles at Controlled Release Society Annual Meeting
3. Making nanoparticles in artificial cells
4. UCF researchers nanoparticles could someday lead to end of chemotherapy
5. Novel approach estimates nanoparticles in environment
6. Nanoparticles May Help Attack Cancer More Directly
7. Stanford researchers harness nanoparticles to track cancer-cell changes
8. Team Designs Gold Nanoparticles to Deliver Multiple Drugs
9. Gold nanoparticles for controlled drug delivery
10. Nanoparticles trigger cell death?
11. Consumers Union Urges FDA to Conduct Full Scale Safety Review of Nanoparticles in Sunscreen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... ... AlignLife clinics nationwide are giving back to their communities by collecting toys ... gifts wrapped tightly under a Christmas Tree. AlignLife hopes to spread the joy ... In exchange for generous donations, customers will receive a gift in return. Anyone ...
(Date:12/7/2016)... ... ... Facial plastic surgeon, Dr. John D. Rachel of Timeless You™ Chicago , ... local organizations: North Chicago Animal Control and Friends and Our House of Hope Rescue. ... and trained volunteers who support rescued animals held in the City of North Chicago’s ...
(Date:12/7/2016)... California (PRWEB) , ... December 07, 2016 , ... "ProBrand ... any and all media," said Christina Austin - CEO of Pixel Film Studios. , ... with easy to use drop zones. Editors can select from a variety of flip ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Tomorrow Trump Goes To Washington”: a brief ... the presidency and to America. “Tomorrow Trump Goes To Washington” is the creation of ... can for this country. , Nancy attributes her patriotic nature to her WWII veteran ...
(Date:12/7/2016)... WI (PRWEB) , ... December 07, 2016 , ... ... Labs, was honored to present at the International Probiotic Association’s Washington DC workshop ... and government regulators to engage in dialog regarding probiotic dietary supplement regulations. ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... , Dec. 6, 2016 Radioisotopes are ... Radioisotopes are produced either by using nuclear research reactor ... the form of alpha, beta or gamma when changed ... are used in Nuclear medicine, specifically in medical diagnostics. ... diagnostic information about a human body,s functioning. Radiotherapy is ...
(Date:12/6/2016)... Dec. 6, 2016 Human Vaccines Market: ... region wise and country wise analysis of the ... manufacturers of human vaccines products, raw material suppliers, ... enter the market. The report provides qualitative ... market. Qualitative analysis comprises market dynamics, trends, product ...
(Date:12/6/2016)... Two new disaster drones delivered telemedical packages ... casualty event Tuesday at John Bell Airport in ... an audience including Mississippi Governor ... Federal Law Enforcement Agencies, and the United Nations. ... Integrated Rescue Operations), was developed by Italo Subbarao ...
Breaking Medicine Technology: